Desire Disorders

Desire Disorders: Intro - Low Libido Lowdown

• Hypoactive Sexual Desire Disorder (HSDD): Defined as persistently or recurrently deficient (or absent) sexual/erotic thoughts or fantasies and desire for sexual activity.
• Must cause clinically significant personal distress.
• Diagnostic duration: Symptoms typically present for ≥6 months.
• Not better accounted for by:
  • A nonsexual mental disorder.
  • Severe relationship distress or other significant stressors.
  • Effects of a substance/medication or another medical condition.
• Key DSM-5 Specifiers: Lifelong vs. Acquired; Generalized vs. Situational.
• Female Sexual Interest/Arousal Disorder (FSIAD): In DSM-5, this diagnosis is used for women, often encompassing low desire and/or arousal difficulties.

⭐ The presence of personal distress is crucial for differentiating HSDD from naturally low, but non-distressing, levels of sexual desire.

Desire Disorders: Etiology - Desire Dampeners

• Multifactorial Origin: Biological, psychological, interpersonal, sociocultural.
• Medical Conditions:
  • Chronic illness: Diabetes, CVD, CKD, chronic pain.
  • Endocrine: Hypothyroidism, hyperprolactinemia, hypogonadism (↓Testosterone/Estrogen).
  • Pelvic issues: Endometriosis, PID, severe dyspareunia.
• Psychological Factors:
  • Mood disorders: Depression, anxiety.
  • Stress (chronic).
  • Past trauma (e.g., sexual abuse).
  • Negative body image.
• Medications (Iatrogenic): 📌 S.H.A.P.O.
  • SSRIs (e.g., paroxetine), SNRIs.
  • Hormonal agents (some OCPs, GnRH analogs, anti-androgens).
  • Antihypertensives (β-blockers, spironolactone).
  • Psychotropics (some antipsychotics like risperidone).
  • Opioids.
• Relationship & Lifestyle:
  • Interpersonal conflict, lack of intimacy.
  • Substance abuse (alcohol, drugs), fatigue.

⭐ Among medications, SSRIs are frequently implicated in reducing libido; consider bupropion as an alternative if depression coexists.

Desire Disorders: Diagnosis - Interest Investigation

Core Evaluation:

• Detailed history: Key to diagnosis. Sexual (onset, duration, context), medical (comorbidities, medications like SSRIs), psychosocial (mood, relationship quality).
• Focused physical exam: Rule out organic causes. Signs of systemic illness, endocrine dysfunction (e.g., hypogonadism).

Screening Tools:

• Validated Questionnaires: e.g., FSFI (Female Sexual Function Index - desire domain), DSDS (Decreased Sexual Desire Screener).

Investigations (clinically guided):

• Hormonal assays: Testosterone (total/free), prolactin, TSH.
• Metabolic screen: Consider HbA1c, lipid profile.

Psychological Assessment:

• Evaluate for depression, anxiety, significant stressors, relationship distress.

⭐ Crucial: Always assess for underlying depression or medication side effects (e.g., SSRIs, anti-hypertensives) as common reversible causes of low desire.

Desire Disorders: Management - Libido Lifelines

• Core Strategy: Biopsychosocial approach; address contributing factors.
• Non-Pharmacological (Often First-Line):
  • Psychosexual education & counseling: Correct misconceptions, improve communication.
  • Cognitive Behavioral Therapy (CBT): Target negative thoughts/beliefs about sex.
  • Sensate focus exercises: Reduce performance anxiety, enhance intimacy. (📌 Masters & Johnson)
  • Mindfulness-based interventions: Improve body awareness & acceptance.
• Pharmacological (Specific Indications):
  • Female (Generalized Acquired HSDD, Premenopausal):
    • Flibanserin (Addyi®): Daily oral; 5-HT1A agonist/5-HT2A antagonist.
    • Bremelanotide (Vyleesi®): Subcutaneous, as-needed; melanocortin receptor agonist.
  • Male (HSDD with Hypogonadism):
    • Testosterone Replacement Therapy (TRT): After confirming low testosterone.
  • Bupropion: May help if SSRI-induced.
• Crucial: Manage comorbidities (depression, anxiety) & relationship issues.

⭐ Flibanserin requires 4 weeks of daily use to assess efficacy and carries a boxed warning for hypotension and syncope, especially with alcohol.

High‑Yield Points - ⚡ Biggest Takeaways

• Hypoactive Sexual Desire Disorder (HSDD) is the most common female sexual dysfunction.
• Characterized by persistent lack of sexual thoughts, fantasies, or desire, causing marked personal distress.
• Exclude desire issues from relationship conflicts, medical illness, or substance/medication effects.
• A biopsychosocial approach is essential for comprehensive assessment and management.
• Management includes sex therapy/psychotherapy (CBT) and FDA-approved medications (e.g., Flibanserin).
• Always evaluate for underlying mood disorders (depression, anxiety) or endocrine dysfunction.